Loading...
Docoh

Allogene Therapeutics (ALLO)

Utility
Methods for Transducing Immune Cells
11 Aug 22
Provided herein are improved methods for transducing immune cells, such as T cells, with retroviral vectors to express exogenous gene products, such as chimeric antigen receptors (CARs).
Todd LUMAN, Josergio ZARAGOZA, Abraham GERMANSDERFER, Suma RAO, Yajin NI, Chupei ZHANG, Tom Tao HUANG
Filed: 28 Jan 22
Utility
KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
11 Aug 22
Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions.
Michael Thomas BETHUNE, Eric Hans GSCHWENG, Thomas John VAN BLARCOM, Cesar Adolfo SOMMER, Michael C YI
Filed: 28 Jan 22
Utility
Formulations and Processes for Car T Cell Drug Products
4 Aug 22
Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.
Muneeswara Babu MEDI, Zhuojin XU, Jung S. LEE, Yajin NI, Mark W. LEONARD
Filed: 3 Feb 22
Utility
Modified CASPASE-9 Polypeptides and Methods of Use Thereof
28 Jul 22
Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides.
Meritxell GALINDO CASAS, Thomas John VAN BLARCOM
Filed: 8 Apr 22
Utility
Protease-activating CD45-GATE Car
21 Jul 22
A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain.
Shanshan LANG, Thomas John VAN BLARCOM, Michael Thomas BETHUNE, Siler PANOWSKI, Nguyen TAN, Yi ZHANG, Barbra Johnson SASU, Zhe LI
Filed: 21 Dec 21
Utility
Methods and Reagents for Characterizing Car T Cells for Therapies
16 Jun 22
Provided herein are methods, kits and reagents for analyzing attributes of engineered immune cells, such as CAR T cells.
Lillian SEU, Melanie L. GEE, Michael A. BOWEN
Filed: 14 Dec 21
Utility
Modified caspase-9 polypeptides and methods of use thereof
10 May 22
Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides.
Meritxell Galindo Casas, Thomas John Van Blarcom
Filed: 31 Oct 18
Utility
Inhibitory Chimeric Antigen Receptors
3 Feb 22
ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Filed: 26 Jul 21
Utility
Chimeric Antigen Receptors with Enhanced Signaling and Activities and Uses Thereof
27 Jan 22
Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety.
Michael Thomas BETHUNE, Yi ZHANG, Thomas John VAN BLARCOM, Siler PANOWSKI, Barbra Johnson SASU
Filed: 21 Jul 21
Utility
Bcma Car-t Cells with Enhanced Activities
26 Aug 21
Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR).
Regina Junhui LIN, Siler PANOWSKI, Cesar Adolfo SOMMER, Thomas John VAN BLARCOM, Barbra Johnson SASU, Arun BALAKUMARAN
Filed: 24 Feb 21
Utility
Inhibitory chimeric antigen receptors
27 Jul 21
The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
Arvind Rajpal, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Filed: 9 Nov 15
Utility
Chimeric Cytokine Receptors Comprising TGF Beta Binding Domains
4 Mar 21
Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-β ligand or a TGF-β receptor antibody.
Regina Junhui LIN, Siler PANOWSKI, Thomas John VAN BLARCOM, Shanshan LANG, Barbra Johnson SASU
Filed: 28 Aug 20
Utility
Methods of Preparing T Cells for T Cell Therapy
4 Mar 21
Provided herein are methods for preparing T cells for T cell therapy comprising contacting a cell population at a predetermined cell density, with a concentration of an anti-CD3/CD28 nanomatrix and culturing the cells thereby producing a T cell population comprising an increased percentage of at least one T cell subtype.
Yajin NI, Chupei ZHANG, Mark W. LEONARD, Thomas Charles PERTEL
Filed: 2 Sep 20
Utility
Improved T Cell Compositions and Methods
23 Dec 20
The present invention provides compositions and methods that downregulate major histocompatibility class I molecule cell surface expression, and uses of such compositions and methods for improving the functional activities of isolated T cells (e.g., gene-modified antigen-specific T cells, such as chimeric antigen receptor T (CAR-T) cells).
Javier Fernando CHAPARRO RIGGERS, Thomas John VAN BLARCOM, Bijan Andre BOLDAJPOUR
Filed: 17 Apr 18
Utility
Anti-talen Antibodies and Uses Thereof
16 Dec 20
The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
Thomas Charles PERTEL, Barbra Johnson SASU
Filed: 11 Jun 20
Utility
Rituximab-resistant Chimeric Antigen Receptors and Uses Thereof
9 Dec 20
Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells.
Thomas Charles PERTEL, Barbra Johnson SASU, Mark W. LEONARD
Filed: 23 Apr 20
Utility
Methods of Manufacturing Allogeneic Car T Cells
28 Oct 20
Described herein are improved media for culturing immune cells, and methods of use thereof.
Diego A. VARGAS-INCHAUSTEGUI, Thomas Charles PERTEL, Barbra Johnson SASU
Filed: 23 Apr 20
Utility
Antibodies Against 4G7-DERIVED Chimeric Antigen Receptors
21 Oct 20
Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv.
Thomas Charles PERTEL, Barbra Johnson SASU, Tao SAI
Filed: 16 Apr 20
Utility
METHODS FOR ENHANCING TCRab+ CELL DEPLETION
7 Oct 20
Provided herein are improved methods for robust TCR+ cell depletion and production of populations of TCR− cells, which can be beneficial to minimize the GvHD risk in patients receiving allogeneic CAR T cell therapy.
Yajin NI, Hongxiu NING, Janet M. LEE, Mark W. LEONARD
Filed: 19 Mar 20
Utility
Constitutively Active Chimeric Cytokine Receptors
16 Sep 20
Provided herein are constitutively active chimeric cytokine receptors (CACCRs).
Regina Junhui LIN, Thomas John VAN BLARCOM, Siler PANOWSKI, Barbra Johnson SASU
Filed: 27 Feb 20
Patents are sorted by USPTO publication date, most recent first